October 29, 2019
Seattle Genetics Reports Third Quarter 2019 Financial Results
Seattle Genetics has record Adcetris net sales in U.S. and Canada of $167.6 Million in the third quarter, an increase…
Pharmaceuticals, Biotechnology and Life Sciences
Category: North America
October 28, 2019
FDA splits proposed indications for Blueprint Medicines’ avapritinib into two separate NDAs
Blueprint Medicines Corporation said in an update on its New Drug Application (NDA) for avapritinib for the treatment of adults with PDGFRA , that the FDA has said it plans to administratively split the proposed indications for avapritinib into two separate NDAs, one for PDGFRA Exon 18 mutant GIST, regardless of prior therapy, and one for fourth-line GIST.
October 28, 2019
FDA extends the use of Lilleta
FDA has expanded the duration of use of Allergan’s Lilleta to prevent pregnancy for up to six years, after Supplemental…
October 28, 2019
Medpace Holdings third quarter 2019 adjusted net income $27.0 million
Medpace Holdings has posted revenue of $216.2 million in the third quarter of 2019, as it increased 20.6% from revenue…
October 28, 2019
Direct dosing via ingestible technologies improves treatment outcomes gastrointestinal diseases
Progenity has presented data on a study showing the potential for improved efficacy in treating inflammatory bowel disease (IBD) when…
October 28, 2019
Arcus Biosciences Appoints Internationally Distinguished Physician to Board of Directors
HAYWARD, Calif.–(BUSINESS WIRE)–Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies, today announced that Antoni…
October 28, 2019
Mirum Pharmaceuticals announces appointment of new Chief Medical Officer
Mirum Pharmaceuticals has appointed Ed Tucker as Chief Medical Officer, the company said Monday.
October 28, 2019
AstraZeneca posts positive positive progression-free survival (PFS) results in phase III Poseidon trial for 1st-line treatment of stage IV non-small cell lung cancer
AstraZeneca announced Monday that Imfinzi (durvalumab) and IMFINZI Plus Tremelimumab Delayed Disease Progression in Phase III POSEIDON Trial for 1st-Line…
October 28, 2019
MedRhythms in multisite trial at the US top rehab hospitals for its post-stroke walking rehabilitation device
5-Center Study of the Device is Intended to Provide Clinical Data in Support of MedRhythms’ FDA Submission.
October 28, 2019
Actinium trial testing Iomab-B in AML patients still highly encouraging
Actinium Pharmaceuticals on Monday announced key interim findings from the pivotal Phase 3 SIERRA trial of Iomab-B at 50% of total of 150-patient, compared to physician’s choice of salvage chemotherapy in patients age 55 and above with active, relapsed or refractory AML (Acute Myeloid Leukemia).